Biogen Inc. (BIIB)
NASDAQ$139.98
Market Cap
$20.49B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
483 of 924
Rank in Industry
9 of 12
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BIIB Insider Trading Activity
BIIB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,439,271 | 4 | 100 |
Related Transactions
| Singhal Priya | Head of Development | 0 | $0 | 3 | $125,129 | $-125,129 |
| SHERWIN STEPHEN A | director | 0 | $0 | 1 | $1.31M | $-1.31M |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. …
Insider Activity of Biogen Inc.
Over the last 12 months, insiders at Biogen Inc. have bought $0 and sold $1.44M worth of Biogen Inc. stock.
On average, over the past 5 years, insiders at Biogen Inc. have bought $918,558 and sold $2.41M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 455 shares for transaction amount of $101,256 was made by Rowinsky Eric K (director) on 2024‑02‑15.
List of Insider Buy and Sell Transactions, Biogen Inc.
| 2025-03-07 | Sale | SHERWIN STEPHEN A | director | 8,760 0.0059% | $150.02 | $1.31M | -5.58% | |
| 2024-12-09 | Sale | Singhal Priya | Head of Development | 110 <0.0001% | $157.21 | $17,293 | -8.01% | |
| 2024-09-03 | Sale | Singhal Priya | Head of Development | 431 0.0003% | $204.22 | $88,019 | -23.13% | |
| 2024-04-02 | Sale | Singhal Priya | Head of Development | 93 <0.0001% | $213.09 | $19,817 | -6.52% | |
| 2024-02-22 | Sale | Singhal Priya | Head of Development | 262 0.0002% | $221.23 | $57,962 | -9.78% | |
| 2024-02-16 | Sale | Singhal Priya | Head of Development | 108 <0.0001% | $221.49 | $23,921 | -8.00% | |
| 2024-02-15 | Rowinsky Eric K | director | 455 0.0003% | $222.54 | $101,256 | -9.74% | ||
| 2024-02-12 | Sale | Singhal Priya | Head of Development | 419 0.0003% | $239.45 | $100,330 | -17.50% | |
| 2024-02-02 | Sale | Singhal Priya | Head of Development | 634 0.0004% | $245.93 | $155,920 | -16.35% | |
| 2023-12-11 | Sale | Singhal Priya | Head of Development | 110 <0.0001% | $248.00 | $27,280 | -11.89% | |
| 2023-09-05 | Sale | Singhal Priya | Head of Development | 431 0.0003% | $269.43 | $116,124 | -14.37% | |
| 2023-07-03 | Sale | Singhal Priya | Head of Development | 81 <0.0001% | $282.87 | $22,912 | -15.65% | |
| 2023-04-28 | Sale | Gregory Ginger | EVP, Human Resources | 2,681 0.0018% | $300.00 | $804,300 | -15.75% | |
| 2023-04-04 | Sale | Singhal Priya | Head of Development | 91 <0.0001% | $277.11 | $25,217 | -5.93% | |
| 2023-03-28 | Sale | Singhal Priya | Head of Development | 568 0.0004% | $270.06 | $153,394 | -3.60% | |
| 2022-11-14 | Sale | Gregory Ginger | EVP, Human Resources | 5,610 0.0039% | $300.11 | $1.68M | -7.22% | |
| 2022-10-27 | Sale | ALEXANDER SUSAN H | EVP Chief Legal Off & Corp Sec | 5,532 0.0039% | $280.70 | $1.55M | +0.80% | |
| 2021-06-07 | Sale | Sandrock Alfred | Head of Research & Development | 7,672 0.0057% | $440.00 | $3.38M | -39.39% | |
| 2021-06-07 | Sale | Guindo Chirfi | Head of Glob Prod Strat & Com | 3,087 0.0023% | $440.00 | $1.36M | -39.39% | |
| 2021-06-04 | Sale | Posner Brian S | director | 360 0.0002% | $274.17 | $98,701 | -15.86% |
Total: 589
*Gray background shows transactions not older than one year
Insider Historical Profitability
9.11%
| DENNER ALEXANDER J | director | 643000 0.4393% | $90.01M | 12 | 4 | +0.39% |
| Vounatsos Michel | Chief Executive Officer | 34810 0.0238% | $4.87M | 5 | 0 | +8.6% |
| Rowinsky Eric K | director | 20629 0.0141% | $2.89M | 1 | 6 | <0.0001% |
| DORSA CAROLINE | director | 17093 0.0117% | $2.39M | 8 | 2 | +28.27% |
| PAPADOPOULOS STELIOS | director | 5000 0.0034% | $699,900.00 | 1 | 2 | <0.0001% |
Historical Insider Profitability vs. Competitors
Biogen Inc. (BIIB) | $364,217,072 | 28 | 9.11% | $20.49B |
$6,077,160 | 24 | 3.21% | $392.42B | |
$1,922,773,492 | 23 | 18.03% | $760.1B | |
$28,542,809 | 19 | 26.40% | $373.46B | |
$23,029,445 | 18 | 9.34% | $122.33B |
BIIB Institutional Investors: Active Positions
| Increased Positions | 418 | +37.9% | 17M | +12.92% |
| Decreased Positions | 486 | -44.06% | 14M | -10.84% |
| New Positions | 125 | New | 2M | New |
| Sold Out Positions | 163 | Sold Out | 3M | Sold Out |
| Total Postitions | 1,035 | -6.17% | 132M | +2.08% |
BIIB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $2.35M | 11.47% | 16.75M | +70,368 | +0.42% | 2024-12-31 |
| Primecap Management Co/Ca/ | $2.25M | 10.99% | 16.05M | -268,870 | -1.65% | 2024-12-31 |
| Blackrock, Inc. | $2.17M | 10.6% | 15.47M | +126,669 | +0.82% | 2024-12-31 |
| State Street Corp | $1.04M | 5.07% | 7.4M | +53,288 | +0.73% | 2024-12-31 |
| Wellington Management Group Llp | $692,767.00 | 3.38% | 4.93M | -200,470 | -3.91% | 2024-12-31 |
| Geode Capital Management, Llc | $519,214.00 | 2.53% | 3.7M | +82,456 | +2.28% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $435,520.00 | 2.12% | 3.1M | -1M | -27.17% | 2024-12-31 |
| Pacer Advisors, Inc. | $374,788.00 | 1.83% | 2.67M | +3M | +13,574.74% | 2024-12-31 |
| Norges Bank | $326,690.00 | 1.59% | 2.33M | +246,454 | +11.86% | 2024-12-31 |
| Invesco Ltd. | $299,097.00 | 1.46% | 2.13M | +499,074 | +30.62% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.